Pfizer presenting on new developments at upcoming ASH meeting

Unable to create scaled Thumbnail image.

The upcoming meeting of the American Society of Hematology (ASH) will feature several presentations of recent data from drug maker Pfizer regarding the company's growing portfolio in hematology compounds.

The compounds include:

Bosutinib against Imatinib in patients with chronic myeloid leukemia (CML), a two-year follow-up from the BELA trial.

Phase III results of an anti-CD22 drug, the investigational antibody drug conjugate Inotuzumab, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma who are not candidates for high-dose chemotherapy.

PF-04449913,an investigational compound that inhibits Smoothened (SMO), a key component of the Hedgehog signaling pathway.

The anti-CD22 immunoconjugate gemtuzumab ozogamicin (Mylotarg) in combination with Rituxan followed by stem cell transplant in patients with relapsed or refractory diffuse large B-cell lymphoma

The 53rd annual meeting of the American Society of Hematology (ASH) will take place this year on December 10-13 in San Diego, California.

Source: MarketWatch

LymphomaInfo Social